Clinical Trial Update: A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma [Phase 3]

View source ↗

Summary

A Phase 3 study compared travoprost 0.004% to latanoprost 0.005% in patients with chronic angle-closure glaucoma to evaluate safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angle-closure Glaucoma
• Ocular Hypertension

Drugs mentioned

• Latanoprost (Latanoprost)
• Travoprost (Travoprost (isomer-free))

Snippet

Sponsor: Alcon Research | Conditions: Glaucoma, Angle-Closure, Ocular Hypertension | Phase 3 | Status: COMPLETED